Credit Suisse Ag Ikena Oncology, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$3.23 - $7.4 $48 - $111	15 New	15 $0
Q4 2021 Feb 14, 2022	SELL	$10.52 - $16.96 $2.1 Million - $3.39 Million	-199,781 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$9.82 - $15.23 $1.01 Million - $1.57 Million	-102,838 Reduced 33.98%	199,781 $2.52 Million
Q2 2021 Aug 16, 2021	BUY	$13.27 - $26.0 $3.69 Million - $7.23 Million	278,197 Added 1139.12%	302,619 $4.25 Million
Q1 2021 May 14, 2021	BUY	$25.6 - $32.0 $625,203 - $781,504	24,422 New	24,422 $690,000

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $61.3M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.